RT Journal Article
SR Electronic
T1 Percentage of reported Covid-19 cases in Colombia: Estimating the true scale of the pandemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.30.20249052
DO 10.1101/2020.12.30.20249052
A1 Nicolás Parra
A1 Vladimir Vargas
A1 Juan Sebastián Flórez
A1 Leonel Ardila
A1 Carlos Viviescas
YR 2021
UL http://medrxiv.org/content/early/2021/01/04/2020.12.30.20249052.abstract
AB Since March 6, when Colombia confirmed its first case of the coronavirus disease (Covid-19), the country healthcare system, with a limited testing capability, has struggled to monitor and report current cases. At the outbreak of a virus, data on cases is sparse and commonly severe cases, with a higher probability of a fatal resolution, are detected at a higher rate than mild cases. In addition, in an under-sampling situation, the number of total cases is under-estimated leading to a biased case fatality rate estimation, most likely inflating the virus mortality. Real time estimation of case fatality ratio can also be biased downwards by overlooking the delay between symptoms onset to death. In this communication, using reported data from Instituto Nacional de Salud up to December 28, we estimate the case fatality rate for Covid-19 in Colombia and some of its regions and cities adjusting for delay from onset to death. We then apply the method proposed by Russell et al. [1], and use our corrected case fatality rate to estimate the percentage of Covid-19 cases reported in Colombia as 42.95% (95% confidence interval: 42.50–43.41), which corresponds to a total of 3’661,621 estimated Covid-19 cases in the country.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human Brain Technologies Phone +57 318 407 9118All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe developed a Python library that eases the extraction, load and transformation of raw data from the INS database. The code is freely available at https://gitlab.com/hubrain/covid19. Also, we designed a dashboard were we keep a daily record of how reporting percentages are changing at each region which can be found at http://covid19.hubrain.co. Furthermore, the code to reproduce the figures and tables here presented is in https://gitlab.com/hubrain/covid19-paper. https://gitlab.com/hubrain/covid19-paper